{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:42:40Z","timestamp":1776321760623,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Solute carrier family 35 member A2 (SLC35A2), which belongs to the SLC35 solute carrier family of human nucleoside sugar transporters, has shown regulatory roles in various tumors and neoplasms. However, the function of SLC35A2 across human cancers remains to be systematically assessed. Insights into the prediction ability of SLC35A2 in clinical practice and immunotherapy response remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We obtained the gene expression and protein levels of SLC35A2 in a variety of tumors from Molecular Taxonomy of Breast Cancer International Consortium, The Cancer Genome Atlas, Gene Expression Omnibus, Chinese Glioma Genome Atlas, and Human Protein Atlas databases. The SLC35A2 level was validated by immunohistochemistry. The predictive value for prognosis was evaluated by Kaplan\u2013Meier survival and Cox regression analyses. Correlations between SLC35A2 expression and DNA methylation, genetic alterations, tumor mutation burden (TMB), microsatellite instability (MSI), and tumor microenvironment were performed using Spearman\u2019s correlation analysis. The possible downstream pathways of SLC35A2 in different human cancers were explored using gene set variation analysis. The potential role of SLC35A2 in the tumor immune microenvironment was evaluated <jats:italic>via<\/jats:italic> EPIC, CIBERSORT, MCP-counter, CIBERSORT-ABS, quanTIseq, TIMER, and xCell algorithms. The difference in the immunotherapeutic response of SLC35A2 under different expression conditions was evaluated by the tumor immune dysfunction and exclusion (TIDE) score as well as four independent immunotherapy cohorts, which includes patients with bladder urothelial carcinoma (BLCA, N = 299), non\u2013small cell lung cancer (NSCLC, N = 72 and N = 36) and skin cutaneous melanoma (SKCM, N = 25). Potential drugs were identified using the CellMiner database and molecular docking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SLC35A2 exhibited abnormally high or low expression in 23 cancers and was significantly associated with the prognosis. In various cancers, SLC35A2 expression and mammalian target of rapamycin complex 1 signaling were positively correlated. Multiple algorithmic immune infiltration analyses suggested an inverse relation between SLC35A2 expression and infiltrating immune cells, which includes CD4+T cells, CD8+T cells, B cells, and natural killer cells (NK) in various tumors. Furthermore, SLC35A2 expression was significantly correlated with pan-cancer immune checkpoints, TMB, MSI, and TIDE genes. SLC35A2 showed significant predictive value for the immunotherapy response of patients with diverse cancers. Two drugs, vismodegib and abiraterone, were identified, and the free binding energy of cytochrome P17 with abiraterone was higher than that of SLC35A2 with abiraterone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study revealed that SLC35A2 is upregulated in 20 types of cancer, including lung adenocarcinoma (LUAD), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), and lung squamous cell carcinoma (LUSC). The upregulated SLC35A2 in five cancer types indicates a poor prognosis. Furthermore, there was a positive correlation between the overexpression of SLC35A2 and reduced lymphocyte infiltration in 13 cancer types, including BRCA and COAD. Based on data from several clinical trials, patients with LUAD, LUSC, SKCM, and BLCA who exhibited high SLC35A2 expression may experience improved immunotherapy response. Therefore, SLC35A2 could be considered a potential predictive biomarker for the prognosis and immunotherapy efficacy of various tumors. Our study provides a theoretical basis for further investigating its prognostic and therapeutic potentials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1155182","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:50:57Z","timestamp":1684396257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2"],"prefix":"10.3389","volume":"14","author":[{"given":"Shengshan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leli","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youbin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-13-0760","article-title":"Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche","volume":"5","author":"Reticker-Flynn","year":"2015","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00305","article-title":"Antibodies against specific Muc16 glycosylation sites inhibit ovarian cancer growth","volume":"12","author":"Rao","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.808584","article-title":"St6gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage","volume":"293","author":"Chakraborty","year":"2018","journal-title":"J Biol Chem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5054","article-title":"N-glycosylation by n-acetylglucosaminyltransferase V enhances the interaction of Cd147\/Basigin with integrin \u03b21 and promotes hcc metastasis","volume":"245","author":"Cui","year":"2018","journal-title":"J Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Rodr\u00cdguez","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of pd-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100717","article-title":"Slc35a2-cdg: novel variant and review","volume":"26","author":"Quelhas","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.mam.2012.12.004","article-title":"Roles of the nucleotide sugar transporters (Slc35 family) in health and disease","volume":"34","author":"Song","year":"2013","journal-title":"Mol Aspects Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/biomedicines9121804","article-title":"Novel insights into the prognosis and immunological value of the Slc35a (Solute carrier 35a) family genes in human breast cancer","volume":"9","author":"Ta","year":"2021","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00749-7","article-title":"Nucleotide sugar transporter Slc35a2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation","volume":"46","author":"Cheng","year":"2023","journal-title":"Cell Oncol (Dordrecht)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/cells10010080","article-title":"Slc35f2, a transporter sporadically mutated in the untranslated region, promotes growth, migration, and invasion of bladder cancer cells","volume":"10","author":"Kotolloshi","year":"2021","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13478","article-title":"Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-\u03b2 type I Receptor\/Apoptosis signal-regulating kinase 1\/Mitogen-activated protein kinase signaling axis","volume":"109","author":"He","year":"2018","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41419-021-04086-9","article-title":"Tmed3 promotes the progression and development of lung squamous cell carcinoma by regulating ezr","volume":"12","author":"Xie","year":"2021","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1142","article-title":"Immune microenvironment composition in non-small cell lung cancer and its association with survival","volume":"9","author":"Tamminga","year":"2020","journal-title":"Clin Trans Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0327-7_17","article-title":"Epic: a tool to estimate the proportions of different cell types from bulk gene expression data","volume":"2120","author":"Racle","year":"2020","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of rna-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"Xcell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-0307","article-title":"Timer: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-0689","article-title":"Tip: a web server for resolving tumor immunophenotype profiling","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase ii Imvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00380","article-title":"Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks","volume":"9","author":"Peixoto","year":"2019","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.08.019","article-title":"Glycosylation in cellular mechanisms of health and disease","volume":"126","author":"Ohtsubo","year":"2006","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.834731","article-title":"A novel signature integrated of immunoglobulin, glycosylation and anti-viral genes to predict prognosis for breast cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/jhg.2011.108","article-title":"Implications of gene copy-number variation in health and diseases","volume":"57","author":"Almal","year":"2012","journal-title":"J Hum Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1042\/ebc20190037","article-title":"The DNA methylation landscape in cancer","volume":"63","author":"Skvortsova","year":"2019","journal-title":"Essays Biochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2015.11.009","article-title":"Cancer immune contexture and immunotherapy","volume":"39","author":"Becht","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.acr.2019.03.006","article-title":"Immunotherapy in breast cancer: current status and future directions","volume":"143","author":"Basu","year":"2019","journal-title":"Adv Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079775","article-title":"Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in Her2-negative breast cancer\u2013a substudy of the neoadjuvant geparquinto trial","volume":"8","author":"Issa-Nummer","year":"2013","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-1459","article-title":"Dendritic cell internalization of \u03b1-galactosylceramide from Cd8 T cells induces potent antitumor Cd8 T-cell responses","volume":"71","author":"Choi","year":"2011","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to pd-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02833-z","article-title":"Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach","volume":"94","author":"Yamamoto","year":"2020","journal-title":"Arch Toxicol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/cancers11020201","article-title":"The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer","volume":"11","author":"Kaderbha\u00ef","year":"2019","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"eLife"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw441","article-title":"Phase I\/Ii trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (Mcrpc) progressing after docetaxel and abiraterone","volume":"28","author":"Massard","year":"2017","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with psa response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1155182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:51:06Z","timestamp":1684396266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1155182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2023.1155182"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1155182","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1155182"}}